All In Biotech

Drug Trial Radar · NCT07410611

ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy

Dynamic ctDNA Monitoring Guides a Single-Arm, Multicenter, Exploratory Study of Befotertinib Combined With Radiotherapy for EGFR-Mutated Oligometastatic NSCLC

Last checked: Nov 19, 2026Latest source record: Feb 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Feb 10, 2026

Primary completion

Feb 28, 2030

Study completion Feb 28, 2030

Sponsor

Lead sponsor
Hebei Medical University Fourth HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Befotertinib is a third-generation EGFR-TKI independently developed in China. In first-line treatment of advanced non-small cell lung cancer (NSCLC) with EGFR mutations, it has demonstrated a median progression-free survival (PFS) of 22.1 months, representing the longest reported PFS data among currently available third-generation EGFR-TKIs. Building on the clinical advantages of this agent and addressing the unmet therapeutic needs in oligometastatic NSCLC, this study aims to conduct a prospective exploration by dynamically monitoring circulating tumor DNA (ctDNA) to guide the application of befotertinib combined with radiotherapy in patients with EGFR mutation-positive oligometastatic NSCLC.

Conditions

  • Patients With Advanced Oligometastatic Non-small Cell Lung Cancer (NSCLC) Who Have Tested Positive for EGFR Mutations Confirmed by Histopathological Examination

Interventions

  • BefotertinibDrug

    Subjects will receive treatment with Befotertinib. Peripheral blood will be collected 8 weeks (±7 days) later for ctDNA testing. Those who test positive for ctDNA will undergo treatment intensification with Befotertinib combined with radiotherapy, while those who test negative will continue with Befotertinib monotherapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free SurvivalTime frame: From date of initiation of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 mont
  2. PFSTime frame: From date of initiation of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 22 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.